OncoMatch/Clinical Trials/NCT05455697
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Is NCT05455697 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for diffuse large b-cell lymphoma.
Treatment: Cyclophosphamide · Doxorubicin · Prednisone · Retifanlimab · Rituximab and Hyaluronidase Human · Tafasitamab · Vincristine · Polatuzumab Vedotin — This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found on B-cells (a type of white blood cell) and some types of cancer cells. Rituximab binds to a protein called CD20, which is also found on B-cells and some cancer cells. These monoclonal antibodies may help the immune system kill cancer cells. Immunotherapy with other monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as CHOP and PolaCHP, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TRR in combination with CHOP or PolaCHP may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-PD-1 therapy
prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Lab requirements
Blood counts
Absolute neutrophil count (ANC) >= 1,000/mcL except in case of marrow infiltration by lymphoma; Platelets >= 75,000/mcL except in cases of marrow infiltration by lymphoma
Kidney function
Serum creatinine clearance (CrCl) >= 30 mL/minute either measured or calculated
Liver function
Serum total bilirubin <= 1.5 x ULN unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma (<= 5 x ULN if so); AST and ALT <= 2.5 x ULN OR <= 5 x ULN for subjects with liver metastases
Cardiac function
Left ventricular ejection fraction of >= 45%, assessed by echocardiography or cardiac multi-gated acquisition (MUGA) scan
ANC >= 1,000/mcL except in case of marrow infiltration by lymphoma; Platelets >= 75,000/mcL except in cases of marrow infiltration by lymphoma; Serum creatinine clearance (CrCl) >= 30 mL/minute; Serum total bilirubin <= 1.5 x ULN unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma (<= 5 x ULN if so); AST and ALT <= 2.5 x ULN OR <= 5 x ULN for subjects with liver metastases; Left ventricular ejection fraction of >= 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify